anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To offer the silver and zinc carrying antibacterial hydroxyapatite which shows safely strong antibacterial power for a long period, heightens a whiteness, and does not cause a change of color by saving it for a long period by allowing hydroxyapatite to absorb and hold water soluble metallic salt of silver and zinc, and thereafter, calcining it. CONSTITUTION:A prescribed quantity of hydroxyapatite is added into a water solution obtained by melting a prescribed quantity of water soluble silver salt and zinc salt, and stirred. After it is stirred enough, a sediment is filtered, washed enough with distilled water, dried, and thereafter, calcined at a prescribed temperature, and thereafter, crushed and target antibacterial hydroxyapatite is obtained. Also, at the time of manufacturing the hydroxypatite by calcium salt and phosphate, water soluble silver salt and zinc salt are allowed to coexist, and thereafter, an obtained sediment is filtered, washed enough with distilled water, dried, and thereafter, calcined by which it is also possible to obtain the hydroxyapatite. The foregoing is desired. As for the zinc quantity allowed to coexist with silver and held, it is necessary that its quantity is at least &gt;=5% by weight against the silver quantity to be held. Also, by executing the calcination at &gt;=961 deg.C being a melting point of silver, the whiteness of powder is further improved.
PROBLEM TO BE SOLVED: To prepare a water-in-oil microemulsion having high safety to a living body by using the ester compd. of a lower alcohol and a higher fatty acid as an oil component and bile acid or its salt as a surfactant and further using an auxiliary activator. SOLUTION: The ester compd. of a 2-6C, preferably 3-4C lower straight chain or branched chain mono- or polyhydric alcohol and a 10-20C, preferably 14-18C straight chain or branched chain satd. or unsatd. fatty acid is, e.g. used as an oil component. Bile acid having &gt;=2 OH groups such as cholic acid, chenodeoxycholic acid or deoxycholic acid or its alkali metallic salt, e.g. used as a surfactant. The ester of a 10-20C, preferably 12-18C fatty aid and sorbitol or glycerol is, e.g. used as an auxiliary activator.
1309039 Amplifying factor of cortisone induction OHUGAI SEIYAKU KK 15 Sept 1971 [19 Sept 1970] 43071/71 Heading A5B An amplifying factor of enzyme induction by cortisone is derived from a microorganism of the family Enterobacteriaceae and is characterized by the following properties: (a) pale yellow colour and hygroscopic, (b) soluble in water to give a yellow solution and gives positive ninhydrin, Folin-Ciocalteu and cystein-sulphuric acid reactions, (c) U.V. and I.R. spectro as in Figs. 1 and 2 respectively, U.V., absorption at 263 mÁ in water and I.R. absorption at 3,300, 1,650, 1,530, 1,390, 1,040 and 830 cm&lt;SP&gt;-1&lt;/SP&gt; by KBr disc method, (d) undergoes decomposition in two stages and (e) M.W. by dextran gel method between 1,357 and 13,000. The microorganism may be of the genus Escherichia Aerobacter, Klebsiella, Paracolobactrum, Alginobacter, Erwinia, Serratia, Salmonella, Proteus or Shigella, e.g. Escherichia Coli, Erwinea aroideae, Erwinia carotovora, Serratia marcescens, Proteus mirabilis, Proteus vulgaris, Proteus morganii, and Aerobacter aerogenes. The factor may be produced by culturing the microorganism in an aqueous nutrient containing a source of carbon, nitrogen and in-  organic salts. The culture broth may be filtered or centrifuged, the insoluble residue extracted with water or saline and the extract added to the soluble part of the culture. The solution so formed may be deproteinized by treatment with perchloric or trichloroacetic acid, absorbed on activated carbon under acidic conditions, and eluted with a KoH/acetone mixture, the eluate neutralized, concentrated and fractionated by column chromatography on dextran gel and fractions collected which have tyrosine transaminase inducing activity.
&lt;P&gt;PROBLEM TO BE SOLVED: To solve the problem that although it is hardly necessary to consider the contamination of powder cosmetics with microorganisms in an unused state, the contamination by mixing with water and from the hands, a cosmetic powder puff, the air and the like has to be considered after starting the use and due to this, an aseptic is incorporated in consideration of antibacterial properties even in these powder cosmetics but sufficient antibacterial activity cannot be obtained with these powder cosmetics.  &lt;P&gt;SOLUTION: A powder cosmetic contains sodium chloride as an essential component. The amount of the sodium chloride incorporated is not particularly limited and normally the sodium chloride may be incorporated in an amount of 0.001-1 wt.%. A preferred amount is 0.01-0.5 wt.%. With amounts of 0.001 wt.% or less the effect is sometimes not sufficient and with amounts of 1 wt.% or more there is no increase in the effect, and such amounts are uneconomical.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The invention discloses a medicament for treating burn and scald. The medicament comprises aqueous agent for coating, wherein the aqueous agent is soaking solution obtained by soaking dittany bark, corktree bark, cotton rose flower, beautyberry, borneol, golden thread and wild jujubes into alcohol. The medicament also comprises medicinal powder for external application, wherein the medicinal powder is formed by grinding processed strychnos, borneol and dragon&#39;s blood into superfine powder and mixing and sterilizing the powder. For pyogenic infection of a patient, the medicinal powder is externally applied to the burn or the scald. The medicament can quickly relieve the initial sharp pain caused by the burn and the scald, and the searing pain is obviously relieved after the medicament is used for 5 to 8 minutes for I and II degrees. The medicament can effectively prevent medium-term infection under scab. The medicament has short treatment period and does not left scars after healing, and even the scars left by I and II-degree burn and scald are not too obvious. The medicament is particularly suitable for I and II-degree burn and scald, and the III-degree or large-area burn and scald are suggested to be treated by combining Chinese (the medicament of the invention) and western medicaments.
The invention relates to a hydrolysis resistant, high molecular weight polymer represented by formula (I), wherein R is alkylene having from 3 to 8 carbon atoms which is optionally substituted with lower alkyl; R1? and R2? are each hydrogen or methyl; wherein R7? and R8? are each alkylene having from 1 to 18 carbon atoms and are optionally substituted with alkyl; the sum of r and t is one or two; R4? and R5? are each independently lower alkyl; R6? is alkyl, aralkyl or alkaryl having from 1 to 8 carbon atoms or N-alkylene lactam having from 3 to 8 carbon atoms; X?- is an anion derived from the group of halogen, SO3?, SO4?, HSO4? and R6?SO4?; M is a copolymerizable vinyl monomer; n has a value of from 10 to 99 mole %; m has a value of from 1 to 90 mole %, p has a value of from 0 to 20 mole % and the sum of m + n + p is 100; q and q&#39; have the same value which is 0 or 1; s is the reciprocal of the number of negative charges in X; and the total amount of monomer represented by subscript m can be from 1 % to 100 % quaternized. The invention also relates to a process for the preparation of the polymer containing low residual monomer and to uses of the polymer.
The present invention addresses the problem of providing a method that enables more accurate suggestions for improving both the health and beauty conditions of a user. A second acquisition unit 121 acquires the user&#39;s gut bacteria data. A score determination unit 122 determines a score that indicates the health level of the gut microbiome of the user on the basis of the gut bacteria data. A type determination unit 123 determines the type to which the user&#39;s gut flora applies, among a plurality of enterotypes, on the basis of the gut bacteria data. An information unit 125 informs suggestions for improving the user&#39;s health condition to the user on the basis of the user&#39;s score and type. The problem is solved thereby.
&lt;P&gt;PROBLEM TO BE SOLVED: To prevent retrieval precision from getting low caused by a dispersion of image quality in a clinical image, when registering the clinical images generated in different environments (different hospitals) in one case information database to be used for retrieval of similar cases.  &lt;P&gt;SOLUTION: This case registration system 2 is provided with a registration request receiving part 21, a case image generation part 22 and a registration part 25. The registration request receiving part (means) 21 receives a registration request including the clinical image from a diagnostic system in the hospital or the like. The case image generation part (means) 22 generates a case image of uniform image quality suitable for the retrieval, by processing the clinical image included in the registration request by an image processing means 23. The registration part (means) 25 registers the case information including the generated case image into the case information database.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
A photoadjuvant immunotherapeutical method includes the steps of providing a phototherapeutical apparatus, comprising a light source, an optical guidance system, and a patient interface; determining a minimal erythema dose; performing phototherapy by irradiating a target surface with the phototherapeutical apparatus; and performing immunotherapy by exposing the irradiated target surface to an antigen. The method can be applied to treat allergic diseases, including allergic rhinitis, rhinoconjunctivitis, asthma, and atopic dermatitis, as well as to treat autoimmune diseases. UVA, UVB and visible light can be used, emitted from a quartz bulb with a small discharge volume. The phototherapy increases the tolerance of a patient&#39;s body toward an antigen. During immunotherapy the irradiated target surface can be exposed to a naturally present antigen or to an administered antigen. The method can be used to treat RSA by preventing rejection of the fotus, or to suppress rejection reactions in organ or cell transplantation.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide live or modified live PRRS vaccine for administration to swine which is of low virulence and gives effective immunity against PRRS.  &lt;P&gt;SOLUTION: A preferred vaccine includes virus isolate having average plaque diameter of less than about 2 mm and low pathogenicity. A preferred vaccine includes a small plaque diameter strain, ATCC Accession No. VR2509. The vaccines according to the invention may be administered to breeding sow or boar and to weaned piglets, and is effective to immunize the swine against both the respiratory and reproductive forms of the disease.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
Dry powder formulations for inhalation, delivery systems, and methods of making and using thereof have been developed. The dry powder formulation contains particles containing (1) an antibody and/or an antibody derivative; and (2) a β-cyclodextrin and/or a β-cyclodextrin derivative. The total amount of the β-cyclodextrin and/or the β-cyclodextrin derivative is at least 50 wt%of the total amount of the antibody and/or antibody derivative and the β-cyclodextrin and/or β-cyclodextrin derivative. The particles of the dry powder formulation have favorable aerodynamic properties, e.g. mass median aerodynamic diameter &lt; 5 μm, fine particle fraction &gt; 40%in cascade impactor study, and emitted fraction &gt;50%. The dry powder formulation can be prepared using spray-drying or spray-freeze-drying. Each administration of the dry powder formulation can deliver to a subject a unit dose of the antibody and/or antibody derivative to prevent, treat, or ameliorate symptom (s) associated with a respiratory disease in the subject.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an image interpretation support system and a program which can improve efficiency of an image interpretation diagnostic work and understanding of a medical examinee regarding the diagnosis or the image interpretation.  &lt;P&gt;SOLUTION: An image read in from a hard disc 9 is displayed on an image display device 15. A CPU 5 of a controller 3 records the displayed image in time series as image information Vn, and at the same time, it records voices inputted by a voice inputting device 21 in time series as voice information S. The start and the finish of the recording are controlled by a button 23. The CPU 5 generates composition data 300 by composing the image information Vn and the voice information S, which are recorded in time series, by making them to correspond to each other in time series when the recording is finished. An external recording device 25 records the composition data 300 in a medium 31.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:To provide the titled promoting agent containing the extract of YOKUININ (speed of adlay) having a specific molecular weight as an active component. CONSTITUTION:Raw or dried YOKUININ is extracted with an alcohol solution having a concentration of &gt;=50wt%, and if necessary, the extract is filtered, and then concentrated by removing the solvent. For the effective extraction of the active component, it is preferable to use ethanol of 50-80% concentration. The extraction is preferably carried out at 40-70 deg.C for several hours - several days. The F-2 fraction obtained by this process is soluble easily in hydrophilic organic solvent, and the objective sebum-secretion promoting agent can be prepared in the form of a peroral drug, drink, transcutaneous drug, etc. by diluting or dissolving the fraction in water or alcohol, etc. Dose: 1-500mg, preferably 10-100mg of the dried F-2 fraction per kg daily. YOKUININ is a traditional crude drug for internal use and is effective to diuretic, antipyretic and anti- inflammatory purposes, etc.
NEW MATERIAL:A compound shown by the formulaI[R1 is H or CH2R(R is phenyl, halogenophenyl, vinyl, or lower cycloalkyl); R2 is lower alkyl; R3 is piperidino, morpholine, or pyrrolidino]. EXAMPLE:4-Pyrrolidino-6-methyl-3-phenyl-4,5,6,7-tetrahydroisooxazolo[5 ,4-b]pyridine. USE:A psychopharmaceutical showing central suppressing action with high selectivity, having low side effects. PROCESS:A compound shown by the formula II is reacted with a compound shown by the formula III in a solvent such as benzene in the presence of a base such as sodium amide, etc. at 0-150 deg.C to give a compound shown by the formula IV. This compound is then subjected to ring opening in a solvent such as toluene, etc. in the presence of a compound shown by the formula V to give a compound shown by the formulaIa. If necessary, this compound is reacted with a compound shown by the formula R1&#39; X(R1&#39; is CH2R; X is halogen), to give a compound shown by the formulaI(R1 is R1&#39;).
FIELD: medicine.SUBSTANCE: invention refers to medicine, specifically dermatology, and may be used for treating experimental leprous infection. For the purpose for suppression of leprous mycobacteria propagation in mice pads infected intraplantarily by Shepard&#39;s method, therapeutic agents are used. The therapeutic agents are presented by a herbal tea. The tea contains ground equal weight proportions of common licorice roots Glycyrrhiza glabra, parviflorous yarrow herb Achillea micrantha and sandy everlasting blossom Helichrisum arenarium. The tea is extracted in prepared 40% aqueous surgical ethanol in the relation of 1 portion of the raw material to 3 portions of ethanol and kept with agitation for 6 days. Then the mixture is added with an equal proportion of a buffer containing, wt %: calcium chloride 0.014, potassium chloride 0.04, potassium dihydrogen phosphate 0.006, magnesium sulphate 0.02, magnesium chloride 0.02, sodium chloride 0.08, sodium bicarbonate 0.035, disodium phosphate 0.024, glucose 0.1. The mixture is kept for another 4 days in a cool place with daily stirring, filtered andoclaved for three times at 0.5 atm for 10 minutes; the prepared extract is introduced into experimental animals in dose 0.4-0.6 mg/kg of body weight daily through a probe into oesophagus.EFFECT: presented invention provides higher therapeutic effectiveness ensured by substantial suppression of leprous mycobacteria growth in mice pads, higher activity of completed phagocytosis M leprae in animal macrophagues, optimal selection of doses with no side effects.5 ex, 10 tbl
Thioamides are prepared by reacting a thionic ester with a metal (e.g. Li, Na or halomagnesium) derivative of a primary or secondary amine.  The process is applicable particularly to the preparation of compounds of the general formula &lt;FORM:1080879/C2/1&gt; wherein R1 represents an alkyl, aralkyl, aryl or alkoxyaryl radical, R2 represents an alkyl, aralkyl, haloaryl, nitroaryl, alkaryl, alkoxyaryl or dialkylaminoalkyl radical, and R3 represents a hydrogen atom or an alkyl radical, from alkyl, aralkyl or aryl esters of acids R1.CS.OH.  The N-disubstituted products of the aliphatic series form methyl iodide addition products of the general formula &lt;FORM:1080879/C2/2&gt; wherein R1 and R11 represent any aliphatic hydrocarbon residues and R111 any hydrocarbon residue.  Thionic esters are prepared by reaction of H2S with imidoesters, preferably in the presence of a base, especially pyridine.  Imidoesters are prepared by the action of alkali, especially anhydrous NH3, on their hydrochlorides obtained by reacting nitriles with absolute ethanol and dry HCl.
In this invention, we extract raw polysaccharides from changium root named A B C respectively, and purify to get 6 polysaccharides I,II,III,IV,V,VI. After sulfation, we get sulfated polysaccharides A1, B1,C1. A1 has two sulfate groups on each monosaccharide at the average while B1 and C1 have three. The sulfated polysaccharides&#39; molecular weight is more than 2 million D. The glycoside link is alpha type. The whole procedure of changium root sulfated polysaccharides is as followings: extract raw polysaccharides from changium root, and then get the polysaccharides sulfated. It is advantageous in simplied-manipulation and low cost. The pharmacological experiments prove its obvious suppression on rat transplanting tumor(S-180) and the reduction of platelet aggregation ratio and whole blood viscosity. It also reduces coagulant time.
PURPOSE:To obtain the titled cleaning and wiping, agent, containing an oil selected from vegetable, animal and synthetic oils and propellant, capable of keeping anal peripheral parts clean and preventing the worsening of various symptoms on the anal peripheral parts, such as hemorrhoids or contact dermatitis. CONSTITUTION:A cleaning and wiping agent obtained by blending (A) 40-97wt.% oil, selected from vegetable oils (e.g. jujube oil or olive oil), animal oils (e.g. squalane or lanolin) and synthetic oils (e.g. glycerol ester of a fatty acid) and having preferably &gt;=30cSt viscosity at 20 deg.C and (B) 2-25wt.% propellant (preferably liquefied gas, freon or dimethyl ether) having preferably 1.2-3.5kg/cm&lt;2&gt; vapor pressure at 20 deg.C. The above-mentioned pharmaceutical is preferably filled in a pressure-resistant vessel equipped with a valve button having 0.33-0.55mm stem diameter, 0.33-1.6mm housing diameter and 0.30-0.80mm button jetting port. If an oil having leaving stickiness in use is employed, 0.5-20wt.% silicone oil is used together to eliminate the stickiness.
PURPOSE:To obtain a composition for oral cavity useful for tooth paste, etc., having excellent foaming property and use feeling and remarkably lowered in stimulation to mucosa of oral cavity by using an anionic surfactant and a specific alkylglycoside fatty acid ester together. CONSTITUTION:An anionic surfactant and an alkylglycoside fatty acid ester in which carbon number of acyl group is 6-22 are used together to provide the objective composition. Especially, an alkylsulfuric acid ester salt (e.g. laurylsulfuric acid sodium salt or myristylsulfuric acid sodium salt) is preferably used as the anionic surfactant. N-lauroylglutamate, N-myristoylglutamate, etc., is blended at an amount of &lt;=0.5% as the anionic surfactant. Fatty acid ester having &gt;=90%, especially &gt;=95% monoester content and having &lt;=1%, especially &lt;=0.5% tri- to poly-ester content is preferably used as the above-mentioned fatty acid ester.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a technique relating to a monoclonal antibody produced by a hybridoma of ATCC Accession No. HB10916.  &lt;P&gt;SOLUTION: The invention provides a monoclonal antibody bondable with a protein specifically recognizable with a monoclonal antibody 5c8 produced by the hybridoma of ATCC Accession No. HB10916. The invention further provides an isolated protein specifically recognizable with a monoclonal antibody 5c8 produced by the hybridoma of ATCC Accession No. HB10916, an isolated nucleic acid molecule encoding a protein specifically recognizable with a monoclonal antibody 5c8 produced by the hybridoma of ATCC Accession No. HB10916, and a human CD4-T cell leukemic cell of ATCC Accession No. CRL 10915 called as D1.1 and capable of essentially imparting a B cell with contact-dependent helper function.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new 9-substituted minocycline compound.  &lt;P&gt;SOLUTION: This new 9-substituted minocycline compound is e.g. expressed by the formula. The naphthyl thiourea part can be made as various substituents such as phenyl urea, phenyl sulfonic acid amide, etc. These minocycline compounds can be used for treating many tetracycline compound-responding states such as bacterial infectious diseases and neoplasm-forming diseases, and further used for e.g. the application to other than the publicly known general uses of the minocycline and tetracycline compounds, such as the inhibition of tetracycline discharge and modification of gene expression.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a transgenic non-human animal inhibiting TROY signals, to provide a transgenic non-human animal having the accentuated substance penetrability of blood brain barriers, and to provide use thereof.  &lt;P&gt;SOLUTION: This transgenic non-human animal inhibiting TROY signals by the expression of dissolvable TROY. The transgenic non-human animal has the accentuated substance penetrability of blood brain barriers. Thereby, the transgenic non-human animal is useful as the model of a disease accompanying the accentuation of the penetration of the blood brain barriers. By the present invention, disease-treating medicines can be screened. Further, a detecting method for detecting the influence of a material on a central nerve by a model animal having the accentuated material permeability of the blood brain barrier is disclosed.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain an oil-in-water type emulsion of high stability by using an oligomeric condensate from fatty acids, glycerol and dicarboxylic acid as well as a specific hydrophilic surfactant as an emulsifier. SOLUTION: Glycerol, a higher straight-chain fatty acid, an aliphatic dicarboxylic acid and a higher branched-chain fatty acid are mixed and esterified to form an oligomeric condensate from glycerol, fatty acids and a dicarboxylic acid. This oligomeric condensate is used together with a hydrophilic surfactant to give the objective oil-in-water emulsion. The hydrophilic surfactant is preferably one or more selected from nonionic surfactants with an HLB of &gt;=10, N-acyl acidic amino acids or their salts. The formulation of a hydrophilic nonionic surfactant is preferably 0.1-20wt.%, particularly 1-10wt.% based on the whole composition and the formulation of the oligomeric condensate is preferably 1-50wt.% based on the whole composition. A cosmetic using this emulsion shows good spreadability on skin and gives freshened feeling after being flown off with water.